Sun Of India To Halt Colon-Cancer Generic In U.S. By July 31
This article was originally published in PharmAsia News
India's Sun Pharma has been ordered by a U.S. federal court to cease marketing its generic version of the Sanofi-Aventis drug Eloxatin (oxaliplatin) for treating colon cancer
You may also be interested in...
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.
One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”